Cytokinetics Inc (CYTK)
54.71
-1.24
(-2.22%)
USD |
NASDAQ |
Nov 14, 16:00
54.71
0.00 (0.00%)
After-Hours: 17:55
Cytokinetics Research and Development Expense (Quarterly)
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
September 30, 2011 | 8.891M |
June 30, 2011 | 10.51M |
March 31, 2011 | 9.179M |
December 31, 2010 | |
September 30, 2010 | 9.547M |
June 30, 2010 | 10.24M |
March 31, 2010 | 9.068M |
December 31, 2009 | 9.822M |
September 30, 2009 | 9.857M |
June 30, 2009 | 10.20M |
March 31, 2009 | 9.959M |
December 31, 2008 | 11.47M |
September 30, 2008 | 13.52M |
June 30, 2008 | 14.86M |
March 31, 2008 | 14.10M |
December 31, 2007 | 13.96M |
September 30, 2007 | 13.22M |
June 30, 2007 | 13.73M |
Date | Value |
---|---|
March 31, 2007 | 12.49M |
December 31, 2006 | 13.03M |
September 30, 2006 | 12.54M |
June 30, 2006 | 12.40M |
March 31, 2006 | 11.27M |
December 31, 2005 | 10.74M |
September 30, 2005 | 9.259M |
June 30, 2005 | 10.04M |
March 31, 2005 | 10.54M |
December 31, 2004 | 11.21M |
September 30, 2004 | 9.535M |
June 30, 2004 | 9.777M |
March 31, 2004 | 9.36M |
December 31, 2003 | |
September 30, 2003 | |
June 30, 2003 | 7.286M |
March 31, 2003 | 7.756M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
Alnylam Pharmaceuticals Inc | 270.93M |
Biomarin Pharmaceutical Inc | 184.90M |
Catalyst Pharmaceuticals Inc | 3.284M |
Sarepta Therapeutics Inc | 224.48M |
Ocugen Inc | 8.902M |